Exelixis | EXEL - Interest Expense On Debt


Exelixis reported $23.4M in Interest Expense on Debt for its fiscal quarter ending in September of 2023.





Interest Expense On Debt Change Date
Acadia Pharmaceuticals USD 0 4.12M Sep/2024
Agios Pharmaceuticals USD 1.06B 44.38M Sep/2026
Akebia Therapeutics 342.13M 7.53M Sep/2026
Amgen USD 653M 94.99B Sep/2026
AstraZeneca USD 371M 31M Sep/2026
Bayer EUR 675M 87M Dec/2025
BioMarin Pharmaceutical USD 55.63M 7.67M Sep/2026
Bristol-Myers Squibb USD 403M 4M Sep/2026
Cytokinetics USD 38.48M 3.65M Sep/2026
Eisai JPY 2.18B 220M Sep/2026
Eli Lilly USD 316M 201.3M Sep/2026
Exelixis USD 23.4M 3.9M Sep/2023
Genmab DKK 139M 129M Jun/2026
Glaxosmithkline GBP 264.74M 72.01M Sep/2026
Incyte USD 605K 23K Sep/2026
Ionis Pharmaceuticals USD 4M 14M Sep/2026
MacroGenics USD 4.4M 493K Jun/2026
Merck USD 525M 46M Jun/2026
Moderna USD 10.96B 527M Jun/2026
Nektar Therapeutics USD 7.94M 1.83M Mar/2026
Neurocrine Biosciences USD 300K 2.6M Sep/2026
Novartis USD 468M 6M Sep/2026
Pfizer USD 662M 5M Sep/2026
Puma Biotechnology USD 3.37M 11K Jun/2024
Sanofi EUR -25M 99.78M Dec/2025
Takeda JPY 63.38B 466M Sep/2026
Ultragenyx Pharmaceutical USD 20M 2M Sep/2026
Xencor USD 4.11M 3.24M Sep/2026